Company Overview and News


Add TRIL
to your dashboard

Headline News

ROTY Edition 1 Volume 54: Performance And Position Updates

2017-11-21 seekingalpha
Biotech sector performance in November has been ¨blah¨, but thankfully ROTY model account returns have been on the upswing. (40-1)

Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

2017-11-20 marketwired
TORONTO, ONTARIO--(Marketwired - Nov. 20, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data for its novel covalent EGFR inhibitor were presented at the Society for Neuro-Oncology 22nd Annual Meeting, November 16-19, in San Francisco. (6-0)

ROTY Edition 1 Volume 52: Material Updates And Trades

2017-11-15 seekingalpha
Performance of the ROTY model account has suffered lately due to both continued weakness in the biotech sector as well as a couple losers that we cut recently. (15-0)

BRIEF-Trillium announces private placement to fund development of cancer drugs

2017-11-15 reuters
* Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​ (6-0)

Trillium Announces Private Placement

2017-11-15 marketwired
TORONTO, ONTARIO--(Marketwired - Nov. 15, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U. (6-0)

Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

2017-11-13 marketwired
TORONTO, ONTARIO--(Marketwired - Nov. 13, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical and clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented this weekend at the Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbor, Maryland USA. (6-0)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

BRIEF-Trillium Therapeutics reports Q3 results

2017-11-10 reuters
* Trillium Therapeutics Inc - ‍Cash and marketable securities of $64.3 million at September 30, 2017​ Source text for Eikon: Further company coverage: (6-0)

Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

2017-11-10 marketwired
- Cash and marketable securities of $64.3 million at September 30; cash burn of $8.3 million in the third quarter (6-0)

ROTY Volume 1 Edition 47: Understanding Mr. Market's Temper Tantrums And Updates

2017-11-07 seekingalpha
I touch on the importance of distinguishing between true high volume institutional selling and momentary temper tantrums thrown by Mr. Market. (98-0)

ROTY Volume 1 Edition 46: Bouncing Back In November And Several New Trades

2017-11-06 seekingalpha
Data from the TiNivo study makes AVEO Pharmaceuticals more attractive to me on multiple time frames and I review the presentation with readers below. (310-7)

Trillium Therapeutics to Present at Upcoming Scientific Conferences

2017-11-06 marketwired
TORONTO, ONTARIO--(Marketwired - Nov. 6, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming scientific conferences. (6-0)

Trillium Therapeutics: The Story Keeps Getting Better

2017-11-06 seekingalpha
I wouldn't be surprised to see a partner come on board in the near to medium term. (6-0)

Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

2017-10-16 marketwired
TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England. (6-0)

CUSIP: 89620X100